Table 6 Performance of prognostic risk stratifications models for thrombosis.

From: Validation of the IPSET score for thrombosis in patients with prefibrotic myelofibrosis

Prognostic model

N (%)

 

Total thrombosis (n = 56)

 
  

N thrombosis

HR (95% CI), P value

C-statistic

Standard risk groupsa

382

  

0.58

 Low risk

171 (45)

22

1 (ref)

 High risk

211 (55)

34

1.74 (1.02–2.99), 0.044

IPSET-thrombosis risk groupsb

356

  

0.63

 Low risk

85 (24)

5

1 (ref)

 Intermediate risk

93 (26)

13

2.81 (1.00–7.91), 0.050

 High risk

178 (50)

32

4.14 (1.61–10.7), 0.003

IPSET-thrombosis revised risk groupsc

370

  

0.62

 Very low risk

72 (19)

4

1 (ref)

 Low risk

98 (27)

17

3.90 (1.31–11.6), 0.014

 Intermediate risk

52 (14)

7

4.14 (1.21–14.2), 0.024

 High risk

148 (40)

24

4.63 (1.60–13.4), 0.005

  1. N(%) indicates the number of patients for whom all required data were available, and the % over total (n = 382).
  2. a“low risk” (age ≤ 60 years and no thrombosis history); “high risk” (age ≥ 60 years and/or thrombosis history).
  3. b“low risk” (tot score 0–1); “intermediate risk” (tot score 2); “high risk” (tot score ≥ 3). Age ≥60 years and at least 1 CV risk factor (1 score); thrombosis history and JAK2 mutation (2 scores).
  4. c“very low risk” (no thrombosis history, age ≤60 years and JAK2-unmutated); “low risk” (no thrombosis history, age ≤60 years and JAK2-mutated); intermediate risk’ (no thrombosis history, age ≥60 years and JAK2-unmutated) and high risk (thrombosis history or age ≥60 years with JAK2 mutation).
Back to article page